AbbVie Wins FDA Approval for Juvmo, but Medicare Timing Could Slow the Parkinson’s Drug Launch
AbbVie’s Juvmo won FDA approval, but missing Medicare’s 2027 window could make the drug’s U.S. launch slower than the regulatory win suggests.
Kodiak Sciences Stock Jumps 90% on Positive Phase 3 AMD Data: What Traders Should Watch Next
Kodiak Sciences shares surged as much as 90% premarket after positive Phase 3 AMD data. Here is what traders may watch next.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Zymeworks Updates 2026 Guidance After Finalizing Theravance Biopharma Deal
Zymeworks has updated its 2026 guidance after finalizing its Theravance Biopharma acquisition, giving investors a cleare…
Kodiak Sciences’ KOD Stock Jumps 65% After DAYBREAK Phase 3 Success
Kodiak Sciences shares reached $54.42 in premarket trading after DAYBREAK met primary endpoints for two eye-treatment ca…
AbbVie’s Parkinson’s Drug Approval Gives ABBV Stock a New October Catalyst
FDA approval for Juvmo gives AbbVie a potential post-Humira growth catalyst ahead of its planned October 2026 U.S. launc…
Mirum’s FDA Approval Puts Rare-Disease Potential in the Spotlight
Mirum Pharmaceuticals’ FDA approval for a rare bone disorder could become an important catalyst for the smaller biopharm…
Outlook Therapeutics Faces a Second FDA Rejection for ONS-5010
A second Complete Response Letter puts renewed focus on the uncertainty of binary FDA decisions for small-cap biotechnol…
Moderna-Merck Cancer Vaccine Trial Success Gives Investors a New Oncology Catalyst
Moderna and Merck cleared a major Phase 3 hurdle, strengthening the case for individualized cancer vaccines and renewed …
Merck’s Oncology Approval Fuels Debate Over a Potential 37% Valuation Discount
Merck’s Welireg-Lenvima approval adds an oncology catalyst as investors weigh a DCF-based 37% undervaluation claim and K…
Mirum Shares Gain as FDA Approval Validates Rare-Disease Drug Strategy
Mirum shares rose 1.0% to $90.23 as FDA approval transformed a key regulatory question into a confirmed catalyst for Nas…
Eli Lilly Expands Olumiant Reach With FDA Approval for Adolescent Alopecia
FDA approval for adolescent alopecia broadens Olumiant’s reach and reinforces Eli Lilly’s immunology strategy beyond GLP…